- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
Patent holdings for IPC class C07D 249/04
Total number of patents in this class: 936
10-year publication summary
|
62
|
55
|
49
|
65
|
62
|
51
|
69
|
53
|
50
|
45
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 358 |
26 |
| Eonhf, Inc. | 45 |
21 |
| The Johns Hopkins University | 5958 |
17 |
| The Regents of the University of California | 20987 |
14 |
| Modernatx, Inc. | 1275 |
13 |
| Yale University | 2582 |
13 |
| Bristol-myers Squibb Company | 4751 |
10 |
| Sigilon Therapeutics, Inc. | 112 |
9 |
| Merck Sharp & Dohme LLC | 3734 |
9 |
| Siemens Medical Solutions USA, Inc. | 1469 |
8 |
| Astex Therapeutics Limited | 200 |
8 |
| Emory University | 1733 |
8 |
| Cantero Therapeutics, Inc. | 11 |
8 |
| Novartis AG | 10160 |
7 |
| Centre National de La Recherche Scientifique | 11143 |
7 |
| ABA Chemicals Corporation | 24 |
7 |
| Nippon Soda Co., Ltd. | 884 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 176 |
7 |
| The Scripps Research Institute | 1345 |
7 |
| The University of Queensland | 649 |
7 |
| Other owners | 723 |